GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascendis Pharma A/S (STU:A71) » Definitions » Cyclically Adjusted PB Ratio

Ascendis Pharma A/S (STU:A71) Cyclically Adjusted PB Ratio : 14.47 (As of Jun. 10, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Ascendis Pharma A/S Cyclically Adjusted PB Ratio?

As of today (2024-06-10), Ascendis Pharma A/S's current share price is €125.00. Ascendis Pharma A/S's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €8.64. Ascendis Pharma A/S's Cyclically Adjusted PB Ratio for today is 14.47.

The historical rank and industry rank for Ascendis Pharma A/S's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:A71' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 6.71   Med: 9.49   Max: 15.97
Current: 14.07

During the past years, Ascendis Pharma A/S's highest Cyclically Adjusted PB Ratio was 15.97. The lowest was 6.71. And the median was 9.49.

STU:A71's Cyclically Adjusted PB Ratio is ranked worse than
94.4% of 661 companies
in the Biotechnology industry
Industry Median: 1.67 vs STU:A71: 14.07

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Ascendis Pharma A/S's adjusted book value per share data for the three months ended in Mar. 2024 was €-4.170. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €8.64 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Ascendis Pharma A/S Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Ascendis Pharma A/S's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascendis Pharma A/S Cyclically Adjusted PB Ratio Chart

Ascendis Pharma A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 12.62

Ascendis Pharma A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.29 8.61 9.23 12.62 15.50

Competitive Comparison of Ascendis Pharma A/S's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Ascendis Pharma A/S's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascendis Pharma A/S's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascendis Pharma A/S's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Ascendis Pharma A/S's Cyclically Adjusted PB Ratio falls into.



Ascendis Pharma A/S Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Ascendis Pharma A/S's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=125.00/8.64
=14.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascendis Pharma A/S's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Ascendis Pharma A/S's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-4.17/118.4000*118.4000
=-4.170

Current CPI (Mar. 2024) = 118.4000.

Ascendis Pharma A/S Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.000 99.700 0.000
201409 0.148 99.700 0.176
201412 2.705 99.400 3.222
201503 6.259 100.200 7.396
201506 5.609 100.300 6.621
201509 5.242 100.200 6.194
201512 4.789 99.800 5.682
201603 4.056 100.200 4.793
201606 3.618 100.600 4.258
201609 2.951 100.200 3.487
201612 5.447 100.300 6.430
201703 4.764 101.200 5.574
201706 3.891 101.200 4.552
201709 5.559 101.800 6.465
201712 5.062 101.300 5.916
201803 8.367 101.700 9.741
201806 7.940 102.300 9.190
201809 7.237 102.400 8.368
201812 6.646 102.100 7.707
201903 15.272 102.900 17.572
201906 14.199 102.900 16.338
201909 13.844 102.900 15.929
201912 12.444 102.900 14.318
202003 11.437 103.300 13.109
202006 9.869 103.200 11.323
202009 17.815 103.500 20.380
202012 15.604 103.400 17.868
202103 14.914 104.300 16.930
202106 12.755 105.000 14.383
202109 17.468 105.800 19.548
202112 15.519 106.600 17.237
202203 12.057 109.900 12.990
202206 10.891 113.600 11.351
202209 7.918 116.400 8.054
202212 4.608 115.900 4.707
202303 2.974 117.300 3.002
202306 1.153 116.400 1.173
202309 -1.299 117.400 -1.310
202312 -2.573 116.700 -2.610
202403 -4.170 118.400 -4.170

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Ascendis Pharma A/S  (STU:A71) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Ascendis Pharma A/S Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Ascendis Pharma A/S's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascendis Pharma A/S (STU:A71) Business Description

Traded in Other Exchanges
Address
Tuborg Boulevard 12, Hellerup, DNK, DK-2900
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.

Ascendis Pharma A/S (STU:A71) Headlines

No Headlines